Published in F1000Res on February 19, 2015
Machine learning models identify molecules active against the Ebola virus in vitro. F1000Res (2015) 0.85
Finding small molecules for the 'next Ebola'. F1000Res (2015) 0.84
In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease. F1000Res (2015) 0.80
The new alchemy: Online networking, data sharing and research activity distribution tools for scientists. F1000Res (2017) 0.75
Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med (2011) 5.30
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife (2012) 5.18
The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med (2011) 3.80
Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform (2011) 2.52
Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother (2014) 1.66
FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med (2013) 1.62
In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today (2011) 1.45
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J (2005) 1.43
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One (2013) 1.38
The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother (2014) 1.35
Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother (2014) 1.34
Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect (2014) 1.18
Repurposing libraries of eukaryotic protein kinase inhibitors for antibiotic discovery. Proc Natl Acad Sci U S A (2009) 1.10
Ebola in west Africa. Lancet Infect Dis (2014) 1.10
Drug repurposing: far beyond new targets for old drugs. AAPS J (2012) 1.09
Ebola by the numbers: The size, spread and cost of an outbreak. Nature (2014) 1.05
A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus. F1000Res (2014) 0.99
Small molecule inhibitors of ebola virus infection. Drug Discov Today (2014) 0.97
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother (2009) 0.95
Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. F1000Res (2015) 0.94
Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Res (2015) 0.92
Expanding the scope of drug repurposing in pediatrics: the Children's Pharmacy Collaborative. Drug Discov Today (2014) 0.91
Small molecules with antiviral activity against the Ebola virus. F1000Res (2015) 0.90
Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity. Antiviral Res (2014) 0.90
Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition. Eur J Pharm Sci (2014) 0.88
In silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy. Cell Prolif (2014) 0.85
Finding small molecules for the 'next Ebola'. F1000Res (2015) 0.84
Finding small molecules for the 'next Ebola'. F1000Res (2015) 0.84